Abstract |
To compare the rate of treatment discontinuation due to adverse events for telaprevir-based triple (T/PR) and pegylated interferon-alfa-2b and ribavirin (PR) therapy for the treatment of hepatitis C virus (HCV) infection in patients over the age of 65 years, in Japan. Retrospective analysis of the health data of patients over the age of 65 years treated for a HCV infection genotype 1 using T/PR or PR therapy, from 38 prefectures in Japan. The primary outcome was the rate of treatment discontinuation due to adverse events for T/PR and PR. The secondary outcome was to evaluate the prevalence and type of adverse events during the treatment period that resulted in treatment discontinuation for both therapies. For comparison, the T/PR and PR populations were matched using the propensity score method, and adjusted odds ratios ( ORs) for treatment discontinuation calculated by multivariate logistic regression analysis. The study group included 1330 patients, 328 in the T/PR group and 1002 in the PR group. The rate of treatment discontinuation due to adverse events in the matched population was lower for T/PR (19.82%) than PR (35.98%) therapy, (adjusted OR, 0.418; 95% confidence interval, 0.292-0.599; p<0.01). Malaise was the principal cause of treatment discontinuation in both groups (T/PR, 30.77%, and PR, 42.37%). Using real-world health data of elderly individuals in Japan, we identified a lower rate of treatment discontinuation for T/PR than PR. Our outcomes provide information for a segment of the population that is generally excluded for clinical trials.
|
Authors | Maiko Akutagawa, Kazuki Ide, Yohei Kawasaki, Mie Yamanaka, Ryo Iketani, Hiroshi Yamada, Naohiko Masaki |
Journal | Biological & pharmaceutical bulletin
(Biol Pharm Bull)
Vol. 40
Issue 9
Pg. 1525-1529
(Sep 01 2017)
ISSN: 1347-5215 [Electronic] Japan |
PMID | 28603159
(Publication Type: Comparative Study, Journal Article)
|
Chemical References |
- Antiviral Agents
- Interferon alpha-2
- Interferon-alpha
- Oligopeptides
- Recombinant Proteins
- Polyethylene Glycols
- Ribavirin
- telaprevir
- peginterferon alfa-2b
|
Topics |
- Aged
- Antiviral Agents
(adverse effects, therapeutic use)
- Drug Therapy, Combination
- Female
- Hepacivirus
- Hepatitis C
(drug therapy, virology)
- Humans
- Interferon alpha-2
- Interferon-alpha
(adverse effects, therapeutic use)
- Japan
- Logistic Models
- Male
- Odds Ratio
- Oligopeptides
(adverse effects, therapeutic use)
- Patient Dropouts
- Polyethylene Glycols
(adverse effects, therapeutic use)
- Recombinant Proteins
(adverse effects, therapeutic use)
- Retrospective Studies
- Ribavirin
(adverse effects, therapeutic use)
|